{"drugs":["Muromonab-CD3","Orthoclone OKT 3"],"mono":{"0":{"id":"386525-s-0","title":"Generic Names","mono":"Muromonab-CD3"},"1":{"id":"386525-s-1","title":"Dosing and Indications","sub":{"0":{"id":"386525-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>Cardiac transplant rejection (Acute), Steroid-resistant:<\/b> 5 mg IV bolus once daily for 10 to 14 days; begin after corticosteroid therapy has failed<\/li><li><b>Liver transplant rejection (Acute), Steroid-resistant:<\/b> 5 mg IV bolus once daily for 10 to 14 days; begin after corticosteroid therapy has failed<\/li><li><b>Renal transplant rejection; Prophylaxis:<\/b> 5 mg IV once daily for 5 to 14 days; begin perioperatively<\/li><li><b>Renal transplant rejection (Acute):<\/b> 5 mg IV bolus once daily for 10 to 14 days; begin upon diagnosis<\/li><\/ul>"},"1":{"id":"386525-s-1-5","title":"Pediatric Dosing","mono":"<ul><li><b>Cardiac transplant rejection (Acute), Steroid-resistant:<\/b> (weight less than 30 kg) 2.5 mg IV bolus once daily for 10 to 14 days; begin after corticosteroid therapy has failed<\/li><li><b>Cardiac transplant rejection (Acute), Steroid-resistant:<\/b> (weight more than 30 kg) 5 mg IV bolus once daily for 10 to 14 days; begin after corticosteroid therapy has failed<\/li><li><b>Liver transplant rejection (Acute), Steroid-resistant:<\/b> (weight less than 30 kg) 2.5 mg IV bolus once daily for 10 to 14 days; begin after corticosteroid therapy has failed<\/li><li><b>Liver transplant rejection (Acute), Steroid-resistant:<\/b> (weight more than 30 kg) 5 mg IV bolus once daily for 10 to 14 days; begin after corticosteroid therapy has failed<\/li><li><b>Renal transplant rejection (Acute):<\/b> (weight less than 30 kg) 2.5 mg IV bolus once daily for 10 to 14 days; begin upon diagnosis<\/li><li><b>Renal transplant rejection (Acute):<\/b> (weight more than 30 kg) 5 mg IV bolus once daily for 10 to 14 days; begin upon diagnosis<\/li><\/ul>"},"3":{"id":"386525-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Cardiac transplant rejection (Acute), Steroid-resistant<\/li><li>Liver transplant rejection (Acute), Steroid-resistant<\/li><li>Renal transplant rejection (Acute)<\/li><\/ul><b>Non-FDA Labeled Indications<\/b><ul><li>Cardiac transplant rejection; Prophylaxis<\/li><li>Graft versus host disease<\/li><li>Renal transplant rejection; Prophylaxis<\/li><\/ul>"}}},"2":{"id":"386525-s-2","title":"Black Box Warning","mono":"<b>Intravenous (Solution)<\/b><br\/>Anaphylactic and anaphylactoid reactions may occur following administration of any dose. Serious, occasionally life-threatening or lethal, systemic, cardiovascular, and central nervous system reactions have been reported. These have included: pulmonary edema, especially in patients with volume overload; shock; cardiovascular collapse; cardiac or respiratory arrest; seizures; coma; cerebral edema; cerebral herniation; blindness; and paralysis. Monitor fluid status prior to and during treatment and premedicate with methylprednisolone to minimize symptoms of Cytokine Release Syndrome.<br\/>"},"3":{"id":"386525-s-3","title":"Contraindications\/Warnings","sub":[{"id":"386525-s-3-9","title":"Contraindications","mono":"<ul><li>fluid overload or uncompensated heart failure, as evidenced by chest x-ray or a greater than 3% weight gain within the week prior to administration<\/li><li>antimouse antibody titers of 1:1000 or greater<\/li><li>hypersensitivity to muromonab-CD3 or any other product of murine origin<\/li><li>hypertension, uncontrolled<\/li><li>pregnancy or breastfeeding<\/li><li>seizures, history or predisposition<\/li><\/ul>"},{"id":"386525-s-3-10","title":"Precautions","mono":"<ul><li>allergic reactions, including immediate, serious, and occasionally fatal anaphylactic and anaphylactoid reactions have been reported in patients following the first dose or subsequent courses of therapy<\/li><li>cerebral edema with subsequent cerebral herniations have been reported; possible increased risk in pediatric patients; fluid status and hypertension must be carefully evaluated prior to initiating therapy; monitoring recommended<\/li><li>CNS adverse events, including encephalopathy, cerebral edema, aseptic meningitis, and headache have been reported; patients with a history of CNS disorders, cerebrovascular disease, conditions with associated neurologic problems (eg, head trauma, uremia, infection, fluid and electrolyte disturbance), underlying vascular disease, and\/or concomitantly receiving a medication that may affect the CNS, may be at increased risk; monitoring recommended<\/li><li>cytokine release syndrome, mild and self-limiting to severe and life-threatening, including fatalities; has been associated with administration of the first few doses;  increased risk of serious outcomes in patients with unstable angina, recent myocardial infarction or symptomatic ischemic heart disease, heart failure, pulmonary edema, COPD, intravascular volume overload or depletion, cerebrovascular disease, advanced symptomatic vascular disease or neuropathy, a history of seizures, or septic shock; pretreatment with methylprednisolone is recommended<\/li><li>pulmonary edema, severe; has occurred; increased risk with fluid overload; assess fluid status (including chest x-ray and weight) prior to drug administration<\/li><li>seizures, in some cases fatal, have occurred<\/li><li>antibodies against muromonab-CD3 have occurred; dose, duration, and type of immunosuppressive therapy directs the incidence and degree of antibody formation<\/li><li>cytomegalovirus and Epstein-Barr virus, reactivation has been reported 1 to 4 months posttransplant<\/li><li>fever; reduce with antipyretics prior to administration<\/li><li>infections, in some cases fatal, have been reported; anti-infective prophylaxis may be warranted in high-risk patients<\/li><li>malignancies (eg, lymphoproliferative disorders, squamous cell carcinomas of the skin and lip, and sarcomas) may occur; increased risk due to immunosuppression; monitoring recommended<\/li><li>pediatric; increased risk of thrombosis and cerebral edema with subsequent cerebral herniations<\/li><li>pediatric patients with primary Epstein-Barr virus; increased risk of developing lymphoproliferative disorder<\/li><li>thromboses of allografts and other vascular beds have been reported; increased risk in patients with a history of thrombosis or underlying vascular disease; treatment is indicated only when potential benefits clearly outweigh treatment risks<\/li><\/ul>"},{"id":"386525-s-3-11","title":"Pregnancy Category","mono":"C (FDA)<br\/>"},{"id":"386525-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"5":{"id":"386525-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Cardiovascular:<\/b>Edema (12%), Hypotension (25%), Tachycardia (26%)<\/li><li><b>Dermatologic:<\/b>Rash (14%)<\/li><li><b>Gastrointestinal:<\/b>Diarrhea (37%), Nausea (32%), Vomiting (25%)<\/li><li><b>Neurologic:<\/b>Headache (28%), Tremor (14%)<\/li><li><b>Respiratory:<\/b>Dyspnea (16%)<\/li><li><b>Other:<\/b>Fever (77%), Shivering (43%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Cardiac dysrhythmia (4%), Hypertension (19%)<\/li><li><b>Dermatologic:<\/b>Stevens-Johnson syndrome<\/li><li><b>Hematologic:<\/b>Thrombosis (less than 1%)<\/li><li><b>Hepatic:<\/b>Hepatitis (less than 1%)<\/li><li><b>Immunologic:<\/b>Anaphylaxis<\/li><li><b>Neurologic:<\/b>Cerebral edema, Encephalopathy (less than 1%), Seizure (1%)<\/li><li><b>Respiratory:<\/b>Pulmonary edema (up to 5%), Respiratory arrest, Respiratory failure<\/li><\/ul>"},"6":{"id":"386525-s-6","title":"Drug Name Info","sub":{"0":{"id":"386525-s-6-17","title":"US Trade Names","mono":"Orthoclone OKT 3<br\/>"},"2":{"id":"386525-s-6-19","title":"Class","mono":"<ul><li>Immunological Agent<\/li><li>Monoclonal Antibody<\/li><\/ul>"},"3":{"id":"386525-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"}}},"7":{"id":"386525-s-7","title":"Mechanism Of Action","mono":"Systemic: Muromonab-CD3, a murine monoclonal antibody , reacts with a T3 (CD3) molecule that is linked to an antigen receptor on the surface membrane of human T lymphocytes and thereby blocks both the generation and function of the T cells in response to antigenic challenge . Initially, binding of muromonab-CD3 to T lymphocytes leads to early activation of T cells and subsequent cytokine release ; however, ultimately, T cell functions are blocked . Muromonab-CD3 does not cause myelosuppression .<br\/>"},"9":{"id":"386525-s-9","title":"Administration","mono":"<b>Intravenous<\/b><br\/><ul><li>draw up solution using 0.2 or 0.22 micron filter; do not shake; discard unused portion<\/li><li>administer as an IV bolus only over less than 1 min; do not administer by IV infusion or with other drug solutions<\/li><\/ul>"},"10":{"id":"386525-s-10","title":"Monitoring","mono":"<ul><li>muromonab-CD3 serum levels greater than or equal to 800 nanograms\/mL or reduced T cell clearance (CD3 positive T cells less than 25 cells per cubic millimeter) are indicative of efficacy; monitor levels periodically in adults and daily in children<\/li><li>CBC with differential; prior to and during therapy<\/li><li>renal function; prior to and during therapy<\/li><li>hepatic function; prior to and during therapy<\/li><li>cytokine release syndrome, particularly after the first few doses and if restarting therapy after treatment interruption<\/li><li>chest x-ray; within 24 hours of initiating therapy<\/li><li>fluid status; prior to and during therapy<\/li><li>lymphoproliferative disorder; physical or histologic evidence<\/li><li>neurologic symptoms; during first 24 hours following first few doses<\/li><li>vital signs, frequently<\/li><\/ul>"},"13":{"id":"386525-s-13","title":"Clinical Teaching","mono":"<ul><li>This drug may cause shivering, diarrhea, nausea, vomiting, arthralgia, myalgia, headache, rigor, dyspnea, fever, malaise, or pulmonary edema.<\/li><li>Instruct patient to report signs\/symptoms of infection.<\/li><li>Advise patients to report signs\/symptoms of neurologic symptoms such as encephalopathy, meningitis, seizures, or cerebral edema. The risk of these adverse events is higher during the first 24 h following the first few doses of muromonab-CD3.<\/li><li>Patient should report signs\/symptoms of serious cardio-respiratory effects such as dyspnea, wheezing, tachypnea, angina, myocardial infarction, tachycardia, hypotension, or arrhythmias.<\/li><\/ul>"}}}